companydata.dkcompanydata.dk

AGC Biologics A/S: Financial statements 2013

CVR: 25950941

Source: annual report 2013, Danish Business Authority

01/01/2013 – 31/12/2013

AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 37,248,000 and a net result of DKK -128,000. Equity in the 2013 report amounted to DKK 136,341,000. The solvency ratio was 43.8%. The company had 185 employees in the financial year.

Gross Profit
DKK 37,248,000
Profit/Loss
DKK -128,000
Equity
DKK 136,341,000
Total Assets
DKK 311,339,000
Employees
185

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

Douglas Robert Sanders steps down as director of AGC Biologics A/SNov 1, 2013

As of November 1, 2013, Douglas Robert Sanders has stepped down as director of AGC Biologics A/S.

AGC Biologics A/S: The 2012 annual report is outJun 2, 2013

AGC Biologics A/S has published its annual report for 2012.

About AGC Biologics A/S

AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.

Source: annual report 2025, Danish Business Authority